Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2012

01-11-2012 | Clinical Trial

A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors

Authors: Jill E. Lavigne, Charles Heckler, Jennifer L. Mathews, Oxana Palesh, Jeffrey J. Kirshner, Raymond Lord, Andrew Jacobs, Eric Amos, Gary R. Morrow, Karen Mustian

Published in: Breast Cancer Research and Treatment | Issue 2/2012

Login to get access

Abstract

Gabapentin is used for the treatment of hot flashes and neuropathic pain in breast cancer survivors, and is commonly used off-label for the treatment of anxiety. Yet, clinical trial evidence to support the use of gabapentin for anxiety symptoms is lacking. In a randomized, double-blinded controlled trial we compared 300 mg gabapentin versus 900 mg gabapentin versus placebo. Subjects were 420 breast cancer patients who had completed all chemotherapy cycles. Anxiety traits and current (state) anxiety were measured using the Speilberger Strait-Trait Anxiety Inventory at baseline, 4 and 8 weeks. Pain was measured at baseline using a 10-point scale. Analyses included analysis of covariance and ordinary least squares regression. At 4 weeks, state anxiety change scores were significantly better for gabapentin 300 and 900 mg (p = 0.005) compared to placebo. The magnitude of improvement was proportional to baseline state anxiety. At 8 weeks, the anxiolytic effects of gabapentin compared to placebo persisted (p < 0.005). We found no significant interactions. The lower dose (300 mg) was associated with the best treatment outcomes for all patients except those with the highest baseline anxiety. Given its similar pharmacology, efficacy in the treatment of hot flashes, and low cost, gabapentin may provide a low cost and parsimonious alternative treatment choice for breast cancer survivors presenting in primary care practices with anxiety symptoms. Gabapentin is effective for hot flashes, and, therefore, may provide therapeutic benefit for both anxiety and hot flashes at a generic drug price. For patients reluctant to take a controlled substance, such as a benzodiazepine, gabapentin may offer an alternative therapy. Similarly, patients with a history of substance use may benefit from gabapentin without risk of addiction or abuse. For cancer survivors experiencing both hot flashes and anxiety, gabapentin may provide a single effective treatment for both and is an alternative therapy for anxiety for patients unwilling to take a benzodiazepine or those with a history of substance use.
Literature
1.
go back to reference Chalasani P, Downey L, Stopeck AT (2010) Caring for the breast cancer survivor: a guide for primary care physicians. Am J Med 123(6):489–495PubMedCrossRef Chalasani P, Downey L, Stopeck AT (2010) Caring for the breast cancer survivor: a guide for primary care physicians. Am J Med 123(6):489–495PubMedCrossRef
2.
go back to reference Khatcheressian J, Wolff A, Smith T et al (2006) American Society of Clinical Oncology 2006 update of breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 24(31):5091–5097PubMedCrossRef Khatcheressian J, Wolff A, Smith T et al (2006) American Society of Clinical Oncology 2006 update of breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 24(31):5091–5097PubMedCrossRef
3.
go back to reference Lavigne JE, Griggs JJ, Tu XM, Lerner DJ. Hot flashes, fatigue, treatment exposures and work productivity in breast cancer survivors. J Cancer Surviv. 2008 Dec;2(4):296–302 Lavigne JE, Griggs JJ, Tu XM, Lerner DJ. Hot flashes, fatigue, treatment exposures and work productivity in breast cancer survivors. J Cancer Surviv. 2008 Dec;2(4):296–302
4.
go back to reference Hartl K, Schennach R, Muller M, Engel J, Reinecker H, Sommer H, Friese K (2010) Quality of life, anxiety, and oncological factors: a follow-up study of breast cancer patients. Psychosomatics 51:112–123PubMed Hartl K, Schennach R, Muller M, Engel J, Reinecker H, Sommer H, Friese K (2010) Quality of life, anxiety, and oncological factors: a follow-up study of breast cancer patients. Psychosomatics 51:112–123PubMed
5.
go back to reference Vahdaninia M, Omidvari S, Montazeri A (2010) What do predict anxiety and depression in breast cancer patients? A follow-up study. Soc Psychiatry Psychiatr Epidemiol 45(3):355–361PubMedCrossRef Vahdaninia M, Omidvari S, Montazeri A (2010) What do predict anxiety and depression in breast cancer patients? A follow-up study. Soc Psychiatry Psychiatr Epidemiol 45(3):355–361PubMedCrossRef
6.
go back to reference Armes J, Crowe M, Colbourne L et al (2009) Patients’ supportive care needs beyond the end of cancer treatment: a prospective, longitudinal survey. J Clin Oncol 27(36):6172–6179PubMedCrossRef Armes J, Crowe M, Colbourne L et al (2009) Patients’ supportive care needs beyond the end of cancer treatment: a prospective, longitudinal survey. J Clin Oncol 27(36):6172–6179PubMedCrossRef
7.
go back to reference Kroenke K, Spitzer RL, Williams JBW, Monahan PO, Lowe B (2007) Anxiety disorders in primary care: prevalence, impairment, comorbidity and detection. Ann Intern Med 146:317–325PubMed Kroenke K, Spitzer RL, Williams JBW, Monahan PO, Lowe B (2007) Anxiety disorders in primary care: prevalence, impairment, comorbidity and detection. Ann Intern Med 146:317–325PubMed
8.
go back to reference Ravindran LN, Stein MB (2010) The pharmacologic treatment of anxiety disorders: a review of progress. J Clin Psychiatry 71:7CrossRef Ravindran LN, Stein MB (2010) The pharmacologic treatment of anxiety disorders: a review of progress. J Clin Psychiatry 71:7CrossRef
9.
go back to reference Pande AC, Feltner DE, Jefferson JW et al (2004) Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled multi-center study. J Clin Psychopharmacol 24:141–149PubMedCrossRef Pande AC, Feltner DE, Jefferson JW et al (2004) Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled multi-center study. J Clin Psychopharmacol 24:141–149PubMedCrossRef
10.
go back to reference Montgomery SA, Tobias K, Zornberg GL et al (2006) Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 67:771–782PubMedCrossRef Montgomery SA, Tobias K, Zornberg GL et al (2006) Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 67:771–782PubMedCrossRef
11.
go back to reference Scheiner FR (2006) Clinical practice: social anxiety disorder. N Engl J Med 355:1029–1036CrossRef Scheiner FR (2006) Clinical practice: social anxiety disorder. N Engl J Med 355:1029–1036CrossRef
12.
go back to reference Landmark CJ (2008) Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs 22(1):27–47CrossRef Landmark CJ (2008) Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs 22(1):27–47CrossRef
13.
go back to reference Jacox A, Carr DB, Payne R, et al. (1994) Management of cancer pain. Clinical practice guideline no. 9. AHCPR publication no. 94-0592. Agency for Health Care Policy and Research, U.S. Department of Health and Human Services, Public Health Service, Rockville Jacox A, Carr DB, Payne R, et al. (1994) Management of cancer pain. Clinical practice guideline no. 9. AHCPR publication no. 94-0592. Agency for Health Care Policy and Research, U.S. Department of Health and Human Services, Public Health Service, Rockville
14.
go back to reference Keskinbora K, Pekel EF, Aydinli I (2007) Gabapentin and an opioid combination versus opioid alone for the management of neuropathic cancer pain: a randomized open trial. J Pain Symptom Manage 34:183–189PubMedCrossRef Keskinbora K, Pekel EF, Aydinli I (2007) Gabapentin and an opioid combination versus opioid alone for the management of neuropathic cancer pain: a randomized open trial. J Pain Symptom Manage 34:183–189PubMedCrossRef
15.
go back to reference Caraceni A, Zecca E, Bonezzi C et al (2004) Gabapentin for neuropathic cancer pain: a randomized, controlled trial from the gabapentin cancer pain study group. J Clin Oncol 22:2909–2917PubMedCrossRef Caraceni A, Zecca E, Bonezzi C et al (2004) Gabapentin for neuropathic cancer pain: a randomized, controlled trial from the gabapentin cancer pain study group. J Clin Oncol 22:2909–2917PubMedCrossRef
16.
go back to reference Caraceni A, Brunelli C, Martini C et al (2005) Cancer pain assessment in clinical trials. A review of the literature. J Pain Symptom Manage 29:507–519PubMedCrossRef Caraceni A, Brunelli C, Martini C et al (2005) Cancer pain assessment in clinical trials. A review of the literature. J Pain Symptom Manage 29:507–519PubMedCrossRef
17.
go back to reference Fassoulaki A, Triga A, Melemeni A et al (2005) Multimodal analgesia with gabapentin and local anesthetics prevents acute and chronic pain after breast surgery for cancer. Anesth Analg 101:1427–1432PubMedCrossRef Fassoulaki A, Triga A, Melemeni A et al (2005) Multimodal analgesia with gabapentin and local anesthetics prevents acute and chronic pain after breast surgery for cancer. Anesth Analg 101:1427–1432PubMedCrossRef
18.
go back to reference Menigaux C, Adam F, Guignard B, Sessler DI, Chauvin M (2005) Preoperative gabapentin decreases anxiety and improves early functional recovery from knee surgery. Anesth Analg 100:1394–1399PubMedCrossRef Menigaux C, Adam F, Guignard B, Sessler DI, Chauvin M (2005) Preoperative gabapentin decreases anxiety and improves early functional recovery from knee surgery. Anesth Analg 100:1394–1399PubMedCrossRef
19.
go back to reference Caraceni A, Portenoy RK (1999) A working group of the IASP task force on cancer pain. An international survey of cancer pain characteristics and syndromes. Pain 82:263–274PubMedCrossRef Caraceni A, Portenoy RK (1999) A working group of the IASP task force on cancer pain. An international survey of cancer pain characteristics and syndromes. Pain 82:263–274PubMedCrossRef
20.
go back to reference Pandya KJ, Morrow GR, Roscoe JA et al (2005) Gabapentin for hot flashes in 420 women with breast cancer: a randomized double-blind placebo-controlled trial. Lancet 366:818–824PubMedCrossRef Pandya KJ, Morrow GR, Roscoe JA et al (2005) Gabapentin for hot flashes in 420 women with breast cancer: a randomized double-blind placebo-controlled trial. Lancet 366:818–824PubMedCrossRef
21.
go back to reference Speilberger CD, Gorsuch RL, Luschene R (1970) STAI manual for the state-trait anxiety inventory. Consulting Psychologists, Palo Alto Speilberger CD, Gorsuch RL, Luschene R (1970) STAI manual for the state-trait anxiety inventory. Consulting Psychologists, Palo Alto
22.
go back to reference Beaver K, Tysver-Robinson D, Campbell M, Twomey M, Williamson S, Hindley A et al (2009) Comparing hospital and telephone follow-up after treatment for breast cancer: randomized equivalence trial. BMJ 338:s3147CrossRef Beaver K, Tysver-Robinson D, Campbell M, Twomey M, Williamson S, Hindley A et al (2009) Comparing hospital and telephone follow-up after treatment for breast cancer: randomized equivalence trial. BMJ 338:s3147CrossRef
23.
go back to reference Van den Bergh R, Essink-Bot ML, Roobol MJ et al (2009) Anxiety and distress during active surveillance for early prostate cancer. Cancer 115(17):386–3878 Van den Bergh R, Essink-Bot ML, Roobol MJ et al (2009) Anxiety and distress during active surveillance for early prostate cancer. Cancer 115(17):386–3878
24.
go back to reference Den Oudsten BL, Van Heck GL, Van der Steeg AFW, Roukema JA, DeVries J (2009) The WHOQOL-100 has good psychometric properties in breast cancer patients. J Clin Epidemiol 62(2):195–205CrossRef Den Oudsten BL, Van Heck GL, Van der Steeg AFW, Roukema JA, DeVries J (2009) The WHOQOL-100 has good psychometric properties in breast cancer patients. J Clin Epidemiol 62(2):195–205CrossRef
25.
go back to reference Fenlon DR, Corner JL, Haviland J (2009) Menopausal hot flushes after breast cancer. Eur J Cancer Care 18(2):14–148CrossRef Fenlon DR, Corner JL, Haviland J (2009) Menopausal hot flushes after breast cancer. Eur J Cancer Care 18(2):14–148CrossRef
26.
go back to reference Cundy K, Annamalai T, Bu L, De Vera J, Estrela J, Luo W, Shirsat P, Torneros A, Yao F, Zou J, Barrett RW, Gallop MA (2004) XP13512: a novel gabapentin prodrug: II. Improved oral availability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther 311:324–333PubMedCrossRef Cundy K, Annamalai T, Bu L, De Vera J, Estrela J, Luo W, Shirsat P, Torneros A, Yao F, Zou J, Barrett RW, Gallop MA (2004) XP13512: a novel gabapentin prodrug: II. Improved oral availability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther 311:324–333PubMedCrossRef
27.
go back to reference Laird B, Colvin L, Fallon M (2008) Management of cancer pain: basic principles and neuropathic cancer pain. Eur J Cancer 48:1078–1082CrossRef Laird B, Colvin L, Fallon M (2008) Management of cancer pain: basic principles and neuropathic cancer pain. Eur J Cancer 48:1078–1082CrossRef
29.
go back to reference Vaidya R, Sood R, Karlin N, Jatoi A (2011) Benzodiazepine use in breast cancer survivors: findings from a consecutive series of 1000 patients. Oncology 81:9–11PubMedCrossRef Vaidya R, Sood R, Karlin N, Jatoi A (2011) Benzodiazepine use in breast cancer survivors: findings from a consecutive series of 1000 patients. Oncology 81:9–11PubMedCrossRef
30.
go back to reference Orriols L, Phillip P, Moore N et al (2011) Benzodiazepine-like hypnotics and the associated risk of road traffic accidents. Clin Pharmacol Ther 89(4):595–601PubMedCrossRef Orriols L, Phillip P, Moore N et al (2011) Benzodiazepine-like hypnotics and the associated risk of road traffic accidents. Clin Pharmacol Ther 89(4):595–601PubMedCrossRef
31.
go back to reference Cole J, Kando J (1993) Adverse behavioral events reported in patients taking alprazolam and other benzodiazepines. J Clin Psychiatry 54:49–63PubMed Cole J, Kando J (1993) Adverse behavioral events reported in patients taking alprazolam and other benzodiazepines. J Clin Psychiatry 54:49–63PubMed
32.
go back to reference Lader M (1999) Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified? Eur Neuropsychopharmacol 9:s399–s940PubMedCrossRef Lader M (1999) Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified? Eur Neuropsychopharmacol 9:s399–s940PubMedCrossRef
33.
go back to reference Baldwin D, Woods R, Lawson R (2011) Efficacy of drug treatments for generalized anxiety disorder: systemic review and meta-analysis. BMJ 342:d1199PubMedCrossRef Baldwin D, Woods R, Lawson R (2011) Efficacy of drug treatments for generalized anxiety disorder: systemic review and meta-analysis. BMJ 342:d1199PubMedCrossRef
Metadata
Title
A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors
Authors
Jill E. Lavigne
Charles Heckler
Jennifer L. Mathews
Oxana Palesh
Jeffrey J. Kirshner
Raymond Lord
Andrew Jacobs
Eric Amos
Gary R. Morrow
Karen Mustian
Publication date
01-11-2012
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2012
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-012-2251-x

Other articles of this Issue 2/2012

Breast Cancer Research and Treatment 2/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine